Biocartis Issues Q3 Update, Raises €32.7M, Inks US Distribution Deal

Nov 17, 2016

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis Group issued an update on its business during the third quarter of fiscal year 2016, and announced €32.7 million ($34.7 million) in private financing and a US distribution deal with Thermo Fisher Scientific for its Idylla diagnostics platform and assays.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

Can Saliva Replace Blood for DNA Collection and Analysis?

Discovering Neuronal Cell Types

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Main menu